Yeşilipek, M. AkifUygun, VedatKüpesiz, AlphanKarasu, GülsünÖztürk, GülyüzErtem, MehmetŞaşmaz, İlgenDaloğlu, HayriyeGüler, ElifHazar, VolkanFisgin, TunçSezgin, GülayKansoy, SavaşKuşkonmaz, BarışAkıncı, BurcuÖzbek, Namıkİnce, Elif ÜnalÖztürkmen, SedaKüpesiz, Funda TayfunYalçın, KorayAnak, SemaBozkurt, CeyhunKarakukcu, MusaKüpeli, SerhanAlbayrak, DavutOniz, HaldunAksoylar, SerapOkur, Fatma VisalAlbayrak, CananYenigürbüz, Fatma DemirBozkaya, İkbal Okİleri, TaliaGürsel, OrhanKaragün, Barbaros ŞahinKintrup, Gülen TuysuzÇelen, SunaElli, MuratAksoy, Başak AdaklıYılmaz, EbruTanyeli, AtilaAkyol, Şule TuranSIVI, Zuhal ÖnderÖzek, GülçihanUçkan, DuyguKartal, İbrahimAtay, DidemAkyay, ArzuBilir, Özlem ArmanÇakmakl, Hasan FatihKürekçi, EminMalbora, BarışAkbayram, SinanDemir, Hacı AhmetKılıç, Suar ÇakırGüneş, Adalet MeralZengin, EmineÖzmen, SalihAntmen, Ali Bülent2024-12-042024-12-042022-02-240268-3369https://doi.org/10.1038/s41409-022-01613-whttps://www.nature.com/articles/s41409-022-01613-whttps://hdl.handle.net/11452/48887We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.eninfo:eu-repo/semantics/closedAccessBone-marrow-transplantationCord blood transplantationLong-termChildrenDiseaseDonorScience & technologyLife sciences & biomedicineBiophysicsOncologyHematologyImmunologyTransplantationArticle00076187280000376076757510.1038/s41409-022-01613-w1476-5365